Cargando…
Alzheimer's disease drug development pipeline: 2017
INTRODUCTION: There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. METHODS: We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed...
Autores principales: | Cummings, Jeffrey, Lee, Garam, Mortsdorf, Travis, Ritter, Aaron, Zhong, Kate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651419/ https://www.ncbi.nlm.nih.gov/pubmed/29067343 http://dx.doi.org/10.1016/j.trci.2017.05.002 |
Ejemplares similares
-
Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018) -
Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019) -
Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020) -
Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023) -
Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)